Paper41438749
Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.
Yengo CK and 17 others. Front Immunol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations. Papers, record 41438749. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41438749
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| AIDS Vaccines | Major topic |
| HIV Antibodies | Major topic |
| env Gene Products, Human Immunodeficiency Virus | Major topic |
| HIV-1 | Major topic |
| HIV Infections | Major topic |
| Antibody Formation | Major topic |
| Animals | |
| Mice | |
| Mice, Inbred BALB C | |
| Female | |
| Adjuvants, Immunologic | |
| Antibodies, Neutralizing | |
| Humans | |
| Nanoparticles | |
| Immunoglobulin G |
Source PubMed
Grants11
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21 AI176069 | NIAID NIH HHS | United States | R21AI176069 | PubMed and NIH | NIH RePORTER |
| P01 AI172531 | NIAID NIH HHS | United States | P01AI172531 | PubMed and NIH | NIH RePORTER |
| IK6 BX004607 | BLRD VA | United States | IK6BX004607 | PubMed and NIH | NIH RePORTER |
| I01 BX005616 | BLRD VA | United States | I01BX005616 | PubMed and NIH | NIH RePORTER |
| R01 AI148327 | NIAID NIH HHS | United States | R01AI148327 | PubMed and NIH | NIH RePORTER |
| R01 AI179427 | NIAID NIH HHS | United States | R01AI179427 | PubMed and NIH | NIH RePORTER |
| R01 AI139290 | NIAID NIH HHS | United States | R01AI139290 | PubMed and NIH | NIH RePORTER |
| R01 AI145655 | NIAID NIH HHS | United States | R01AI145655 | PubMed and NIH | NIH RePORTER |
| R01 AI160706 | NIAID NIH HHS | United States | R01AI160706 | PubMed and NIH | NIH RePORTER |
| R01 AI140909 | NIAID NIH HHS | United States | R01AI140909 | PubMed and NIH | NIH RePORTER |
| R21 AI180874 | NIAID NIH HHS | United States | R21AI180874 | PubMed and NIH | NIH RePORTER |
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33370382 | Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. | PLoS Pathog | 2020 | https://conductscience.org/library/papers/33370382 | PubMed |
| 2 | 24352234 | Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. | Nature | 2014 | https://conductscience.org/library/papers/24352234 | PubMed |
| 3 | 33761206 | Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33761206 | PubMed |
| 4 | 25368619 | IgG subclasses and allotypes: from structure to effector functions. | Front Immunol | 2014 | https://conductscience.org/library/papers/25368619 | PubMed |
| 5 | 39489918 | Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant. | Mol Ther | 2024 | https://conductscience.org/library/papers/39489918 | PubMed |
| 6 | 28472280 | Diversification of IgG effector functions. | Int Immunol | 2017 | https://conductscience.org/library/papers/28472280 | PubMed |
| 7 | 33554060 | Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. | iScience | 2021 | https://conductscience.org/library/papers/33554060 | PubMed |
| 8 | 28678869 | V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. | PLoS One | 2017 | https://conductscience.org/library/papers/28678869 | PubMed |
| 9 | 31845904 | Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. | J Clin Invest | 2020 | https://conductscience.org/library/papers/31845904 | PubMed |
| 10 | 33087466 | Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. | J Virol | 2020 | https://conductscience.org/library/papers/33087466 | PubMed |
| 11 | 36119058 | Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. | Front Immunol | 2022 | https://conductscience.org/library/papers/36119058 | PubMed |
| 12 | 26497511 | Mouse and human FcR effector functions. | Immunol Rev | 2015 | https://conductscience.org/library/papers/26497511 | PubMed |
| 13 | 2693365 | Biological role of different antibody classes. | Int Arch Allergy Appl Immunol | 1989 | https://conductscience.org/library/papers/2693365 | PubMed |
| 14 | 32142167 | Antibody-mediated complement activation in pathology and protection. | Immunol Cell Biol | 2020 | https://conductscience.org/library/papers/32142167 | PubMed |
| 15 | 29514914 | Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. | J Virol | 2018 | https://conductscience.org/library/papers/29514914 | PubMed |
| 16 | 33801906 | Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/33801906 | PubMed |
| 17 | 24504509 | Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. | PLoS One | 2014 | https://conductscience.org/library/papers/24504509 | PubMed |
| 18 | 29408873 | Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1. | PLoS One | 2018 | https://conductscience.org/library/papers/29408873 | PubMed |
| 19 | 1636090 | Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. | Science | 1992 | https://conductscience.org/library/papers/1636090 | PubMed |
| 20 | 32491861 | Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus. | Mol Pharm | 2021 | https://conductscience.org/library/papers/32491861 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41438749
GET https://conductscience.org/api/papers/v1/41438749/references?page=2